IT8848118A0 - Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico - Google Patents

Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico

Info

Publication number
IT8848118A0
IT8848118A0 IT8848118A IT4811888A IT8848118A0 IT 8848118 A0 IT8848118 A0 IT 8848118A0 IT 8848118 A IT8848118 A IT 8848118A IT 4811888 A IT4811888 A IT 4811888A IT 8848118 A0 IT8848118 A0 IT 8848118A0
Authority
IT
Italy
Prior art keywords
uridine
pharmacological treatment
disorders due
altered dopamine
balance
Prior art date
Application number
IT8848118A
Other languages
English (en)
Other versions
IT1219667B (it
Inventor
Politi Vincenzo
De Luca Giovanna
Di Stazio Giovanni
Materazzi Mario
Original Assignee
Polifarma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polifarma Spa filed Critical Polifarma Spa
Priority to IT48118/88A priority Critical patent/IT1219667B/it
Publication of IT8848118A0 publication Critical patent/IT8848118A0/it
Priority to CA000600276A priority patent/CA1327003C/en
Priority to JP1150354A priority patent/JPH0623109B2/ja
Priority to EP89830264A priority patent/EP0348360B1/en
Priority to DE68912419T priority patent/DE68912419T2/de
Priority to AT89830264T priority patent/ATE100322T1/de
Priority to US07/367,615 priority patent/US4960759A/en
Priority to KR1019890008467A priority patent/KR900000092A/ko
Application granted granted Critical
Publication of IT1219667B publication Critical patent/IT1219667B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IT48118/88A 1988-06-21 1988-06-21 Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico IT1219667B (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IT48118/88A IT1219667B (it) 1988-06-21 1988-06-21 Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
CA000600276A CA1327003C (en) 1988-06-21 1989-05-24 Pharmacological use of uridine in the treatment of nervous disorders
JP1150354A JPH0623109B2 (ja) 1988-06-21 1989-06-13 脳神経障害治療用薬剤
EP89830264A EP0348360B1 (en) 1988-06-21 1989-06-14 Pharmacological use of uridine in the treatment of nervous disorders
DE68912419T DE68912419T2 (de) 1988-06-21 1989-06-14 Verwendung von Uridin zur Behandlung nervöser Störungen.
AT89830264T ATE100322T1 (de) 1988-06-21 1989-06-14 Verwendung von uridin zur behandlung nervoeser stoerungen.
US07/367,615 US4960759A (en) 1988-06-21 1989-06-19 Pharmacological use of uridine in the treatment of nervous disorders
KR1019890008467A KR900000092A (ko) 1988-06-21 1989-06-20 신경 장애의 치료에 있어서 유리딘의 약리학적 용도

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT48118/88A IT1219667B (it) 1988-06-21 1988-06-21 Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico

Publications (2)

Publication Number Publication Date
IT8848118A0 true IT8848118A0 (it) 1988-06-21
IT1219667B IT1219667B (it) 1990-05-24

Family

ID=11264638

Family Applications (1)

Application Number Title Priority Date Filing Date
IT48118/88A IT1219667B (it) 1988-06-21 1988-06-21 Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico

Country Status (8)

Country Link
US (1) US4960759A (it)
EP (1) EP0348360B1 (it)
JP (1) JPH0623109B2 (it)
KR (1) KR900000092A (it)
AT (1) ATE100322T1 (it)
CA (1) CA1327003C (it)
DE (1) DE68912419T2 (it)
IT (1) IT1219667B (it)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634374B1 (fr) * 1988-07-19 1993-10-15 Laboratoires Serobiologiques Agents photoprotecteurs, cytophotoprotecteurs cutanes ayant une activite photoprotectrice des cellules constitutives, fonctionnelles de la peau, en particulier des cellules de langerhans, a base de composes nucleiques : nucleoprotides, ribonucleotides et desoxyribonucleotides, ribonucleosides et desoxyribonucleosides, compositions cosmetiques ou dermo-pharmaceutiques contenant un tel agent ainsi que des nouveaux composes en soi
WO1994026280A1 (en) * 1993-05-19 1994-11-24 Korea Green Cross Corporation Remedy for arthritis containing uridine as active ingredient
US5962459A (en) * 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
IT1290781B1 (it) * 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
WO2000006174A1 (en) 1998-07-31 2000-02-10 Massachusetts Institute Of Technology Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
NZ513926A (en) 1999-02-23 2001-09-28 Univ California Methods of treatment of mitochondrial disorders
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
US6727231B1 (en) 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
AUPR951101A0 (en) * 2001-12-13 2002-01-24 Centre For Molecular Biology And Medicine Method of treatment
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
US9572830B2 (en) * 2004-05-13 2017-02-21 Massachusetts Institute Of Technology Uridine effects on dopamine release
US8318798B2 (en) 2005-11-24 2012-11-27 National University Corporation Hokkaldo University Therapeutic agent for neurodegenerative disease
EP1897937A1 (en) * 2006-09-07 2008-03-12 NeuroProgen GmbH Leipzig Method of culturing NPCs
CN101896119A (zh) 2007-11-02 2010-11-24 麻省理工学院 尿苷饮食添加顺应性方法及其用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
CN102548555A (zh) 2009-07-31 2012-07-04 克莱拉有限公司 用于治疗帕金森病的组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1178044B (it) * 1984-10-09 1987-09-03 Polifarma Spa Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
JPH0669953B2 (ja) * 1985-08-16 1994-09-07 日産化学工業株式会社 脳脊髄系神経栄養剤
ATE93236T1 (de) * 1987-10-28 1993-09-15 Pro Neuron Inc Acylatiertes uridin und cytidin und deren verwendungen.

Also Published As

Publication number Publication date
ATE100322T1 (de) 1994-02-15
EP0348360A2 (en) 1989-12-27
IT1219667B (it) 1990-05-24
KR900000092A (ko) 1990-01-30
DE68912419D1 (de) 1994-03-03
US4960759A (en) 1990-10-02
CA1327003C (en) 1994-02-15
EP0348360B1 (en) 1994-01-19
EP0348360A3 (en) 1991-10-23
JPH0245425A (ja) 1990-02-15
JPH0623109B2 (ja) 1994-03-30
DE68912419T2 (de) 1994-08-04

Similar Documents

Publication Publication Date Title
IT8848118A0 (it) Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
ATE181917T1 (de) Therapeutische nukleoside
IT1197502B (it) Protesi acustica da inserire nell'orecchio
DK410787D0 (da) Oralt terapeutisk system med systemisk virkning
DK204687D0 (da) Indstillelig dysekonstruktion
DE3855333D1 (de) Therapeutische Nukleoside
KR910002326A (ko) 치료용 뉴클레오시드
ES550532A0 (es) Dispositivo pra producir el blanqueamiento de dientes vitales con coloraciones patologicas y normales.
DK191688D0 (da) Terapeutiske nucleosider
DK406689A (da) Terapeutiske nucleosider
PT86982A (pt) Therapeutic nucleosides
IT8948660A0 (it) Farmaco attivo nel ripristino della plasticita' neuronale
IT1189308B (it) L'impiego in terapeutica d'un derivato dell'acetammide
ITMI912224A0 (it) Impiego di composti adenosinici nel trattamento dell'ischemia
IT1188653B (it) Cianoacetoammido-derivati ad azione antifungina
DK692087A (da) Peptid med renin-inhibitorisk virkning
ES282491Y (es) Sauna individual
KR860005752U (ko) 맛사지겸용 샤워기
IT8603325A1 (it) Microfono perfezionato per fornire effetto stereofonico tridimensionale
KR850009087U (ko) 시계문자판에 부착되는 광고용 악세사리
DK124390A (da) Prostaglandinderivater med antitrombotisk virkning
IT8764818A0 (it) Sottoascella tricia da applicare direttamente all'ascella per assorbire il sudore
BR8602906A (pt) Aperfeicoamento em suspensor de coluna de producao
DK725088A (da) Terapeutiske nucleosider
BR6702918U (pt) Ducha solar

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960621